Third TDM of Biologics SYMPOSIUM
9 December 2022 – Amsterdam Public Library (OBA)

Therapeutic drug monitoring of biologics:
towards personalised medicine


08.30 – 09.15

Registration & welcome coffee

09.15 – 09.45

Opening: Treatment of chronic inflammatory diseases in a personalised way.
Gertjan Wolbink, MD PhD, Reade & Sanquin Research, Amsterdam, The Netherlands


Finding the Therapeutic window

Session chairs: Theo Rispens, PhD & Mark Löwenberg, MD PhD

09.45 – 10.05

Use of TDM of biologics in rheumatology: beyond the NOR-DRUM Study.
Guro L Goll, MD PhD, Diakonhjemmet Hospital, Oslo, Norway

10.05 – 10.25

Personalised dosing in multiple sclerosis: current studies and future prospects.
Zoé van Kempen, MD PhD, Amsterdam University Medical Centre, Amsterdam, The Netherlands

10.25 – 10.40

Optimal cut-off serum levels of biologics in inflammatory bowel disease.
Krisztina Gecse, MD PhD, Amsterdam University Medical Centre, Amsterdam, The Netherlands

10.40 – 11.00

Panel discussion

11.00 – 11.40



Clinical use of TDM of biologics in different pathologies

Session chairs: Annick de Vries, PhD & Gertjan Wolbink, MD PhD

11.40 – 11.55

Good use of expensive drug.
Sjoerd Repping, PhD, Zorgevaluatie en Gepast Gebruik and Amsterdam University Medical Centre, Amsterdam, The Netherlands

11.55 – 12.05

Creating a Network for TDM of biologics: European cooperation in science and technology, ENOTTA.
Denis Mulleman, MD PhD, COST Action Chair, Centre Hospitalier Régional Universitaire de Tours and Université de Tours, Tours, France

12.05 – 12.20

One biologic for multiple diseases, multiple biologics in one disease.
Floris Loeff, PhD, Sanquin Health Solutions, Amsterdam, the Netherlands

12.20 – 12.40

TDM of biologics in oncology – do or don’t?
Rob ter Heine, PhD, Radboud University Medical Centre, Nijmegen, the Netherlands

12.40 – 13.00

Panel discussion

13.00 – 14.10



Deeper understanding of the PK of biologics

Session chairs: Ron Mathôt, PhD & Johan van Limbergen, MD PhD

14.10 – 14.30

Bridging pharmacokinetics and pharmacodynamics.
Theo Rispens, PhD, Sanquin Research, Amsterdam, The Netherlands

14.30 – 14.50

Mechanistic, multi-Scale mathematical model of immunogenicity for therapeutic proteins.
Timothy Hickling, PhD, Roche, Basel, Switzerland

14.50 – 15.10

Panel discussion

15.10 – 15.45



Last hurdles to general implementation of TDM of biologics

Session chairs: Geert D’Haens, MD PhD & Phyllis Spuls, MD PhD

15.45 – 16:05


Charlotte L.M. Krieckaert, MD, PhD Reade Amsterdam The Netherlands

16.05 – 16.20

Clinical application of dashboard systems.
Jurij Hanzel, MD PhD, University Medical Centre Ljubljana, Ljubljana, Slovenia

16.20 – 16.35

Patient perspective on TDM of biologics.
Maureen Leeuw, Msc, Reade, Amsterdam, The Netherlands

16.35 – 17.00

Panel discussion & closing

FAREWELL DRINKS and network reception